Abstract: Objective To evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with bevacizumab in the treatment of advanced epithelial ovarian cancer and its impact on patient prognosis. Methods A total of 146 patients with advanced epithelial ovarian cancer diagnosed and treated at the General Hospital of the Northern Theater Command of the Chinese People's Liberation Army from January 2020 to January 2024 were selected. They were divided into a control group (74 cases, treated with HIPEC) and an intervention group (72 cases, treated with HIPEC + bevacizumab). Treatment was administered for 3 cycles (per cycle 21 days). The efficacy, serum biomarkers, inflammatory factors, quality of life, adverse reactions, and prognosis were compared between the two groups. Results The objective response rate, disease control rate, and quality of life questionnaire core 30 (QLQ-C30) score in the intervention group were higher than those in the control group (P＜0.05). The serum levels of squamous cell carcinoma associated antigen (SCCA), tumor specific growth factor (TSGF), carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), vascular endothelial growth factor (VEGF), serum C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and connective tissue growth factor (CTGF), as well as the incidence of adverse reactions, recurrence and metastasis rate, and mortality in the intervention group were lower than the control group (P＜0.05). Conclusion The combination of HIPEC and bevacizumab can significantly improve the efficacy of patients with advanced epithelial ovarian cancer, optimize serum marker levels, reduce inflammatory responses and adverse events, and improve prognosis and quality of life.